Clinical Trial Update: Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event

View source ↗

Summary

AstraZeneca reports the completion of a secondary prevention treatment trial in patients who have suffered a cardiovascular event. The document provides a statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Snippet

Sponsor: AstraZeneca | Conditions: Cardiovascular Events | Status: COMPLETED